Treatment with the selective ETA antagonist atrasentan (10 mg once daily for 28 days) resulted in a significant increase in plasma ET-1 levels in a study of patients with refractory adenocarcinomas (Carducci et al, 2002). The gene discussed is EDN1; the disease is adenocarcinoma.